Skip to Content

The World’s Most Expensive Medicine Is Being Pulled from the Market

The maker of the gene therapy Glybera says it doesn’t have enough customers.
April 21, 2017
Manufacturing gene therapy at UniQure.

The company that developed the Western world’s first gene therapy will withdraw its pioneering treatment from the market because of a lack of demand.

The drug, Glybera, was the most expensive prescription medication in history at $1 million for a one-time round of injections (see “The World’s Most Expensive Medicine Is a Bust”). It contains engineered viruses carrying copies of a gene meant to correct lipoprotein lipase deficiency, a rare metabolic disease.

Glybera’s approval by European drug regulators in 2012 marked a milestone for the field of gene therapy after a series of setbacks and safety problems. But low demand for the therapy and questions about its effectiveness have plagued Glybera’s manufacturer, UniQure, based in Amsterdam and Lexington, Massachusetts.

“It wasn’t just that it cost $1 million; it’s that it came to market without much evidence basis that it was worth $1 million,” says Casey Quinn, a health economist at the MIT Center for Biomedical Innovation who specializes in European drug pricing.

UniQure said this week that it will not renew the drug’s marketing authorization in Europe when it is scheduled to expire in October. The company will continue to make the drug available to patients until that date.

“The drug’s usage has been extremely limited and we do not envision patient demand increasing materially in the years ahead,” UniQure’s CEO, Matthew Kapusta, said in a company statement.

Quinn says he doesn’t think Glybera’s failure portends trouble for other gene therapies, but the commercial disappointment comes as questions swirl around how future such treatments should be priced.

Several gene-therapy products will be reviewed for approval by U.S. Food and Drug Administration this year, including a treatment for inherited blindness developed by Spark Therapeutics and a novel form of cancer treatment, called CAR-T therapy, being advanced by Novartis and Kite Therapeutics.

Keep Reading

Most Popular

Scientists are finding signals of long covid in blood. They could lead to new treatments.

Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests.

Large language models can do jaw-dropping things. But nobody knows exactly why.

And that's a problem. Figuring it out is one of the biggest scientific puzzles of our time and a crucial step towards controlling more powerful future models.

OpenAI teases an amazing new generative video model called Sora

The firm is sharing Sora with a small group of safety testers but the rest of us will have to wait to learn more.

Google’s Gemini is now in everything. Here’s how you can try it out.

Gmail, Docs, and more will now come with Gemini baked in. But Europeans will have to wait before they can download the app.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.